ReviewInflammopharmacology2026
Curcumin in Behçet's disease: exploring therapeutic potential, evidence, and key research gaps.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet’s disease (BD) is a systemic inflammatory disorder characterized by mucocutaneous ulceration, uveitis, and variable articular, neurological, gastrointestinal, and vascular involvement. BD pathogenesis is multifactorial, involving genetic susceptibility, immune dysregulation, and environmental triggers. Curcumin, a bioactive compound of Curcuma longa, has anti-inflammatory, antioxidant, and immunomodulatory properties. The aim of this study is to review clinical and experimental evidence on the potential therapeutic role of curcumin in BD. Database searches up to November 2025 identified three studies, including two clinical and one experimental. Experimental study demonstrated reduced interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α) expression with curcumin, while clinical findings showed that nanocurcumin decreased disease activity, enhanced regulatory T cell (Treg) markers, and suppressed T helper 17 (Th17)-related cytokines and transcription factors. Although findings suggest potential therapeutic benefit, evidence for curcumin in BD remains limited, warranting larger, well-designed studies.
Indexed as
Identifiers
41879901What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.